EGFR, KRAS, BRAF, PTEN, and PIK3CA mutation in plasma of small cell lung cancer patients

BACKGROUND: Small cell lung cancer (SCLC) is an aggressive and deadly neuroendocrine tumor derived from bronchial epithelial cells. Although it results in a 95% mortality rate, the development of targeted therapies for SCLCs has lagged behind. The aim of this study is to better research mutation cha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Hong-Yang, Qin, Jing, Han, Na, Lei, Lei, Xie, Fajun, Li, Chenghui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916454/
https://www.ncbi.nlm.nih.gov/pubmed/29720878
http://dx.doi.org/10.2147/OTT.S159612

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5916454/
https://www.ncbi.nlm.nih.gov/pubmed/29720878
http://dx.doi.org/10.2147/OTT.S159612

Ejemplares similares